Pulmonary Arterial Hypertension (PAH): Drug Development Pipeline Study, H1 2018

Pulmonary Arterial Hypertension (PAH): Drug Development Pipeline Study, H1 2018

  • March 2018 •
  • 118 pages •
  • Report ID: 5360109 •
  • Format: PDF
53 active drugs and 60+ companies analyzed

Pulmonary Arterial Hypertension (PAH) is a rare and catastrophic condition, with an estimated market value of over $4 billion. The chronic and rapidly progressing disease affects around 0.2 million to 0.3 million people globally.

It is characterized by enlargement of arterial walls within the small pulmonary arteries transporting high pressure blood between the heart and lungs, resulting in strain on the heart and thereby, restricted blood flow. Disease symptoms include breath shortage, chest pain and fainting episodes.

Endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, prostacyclin analogues and soluble guanylate cyclase (sGC) stimulators are the primary treatment options for PAH. However, as the underlying mechanism is yet unknown, the current therapies reduce the effect of PAH but do not impact the underlying cause.

The most comprehensive pipeline review “Pulmonary Arterial Hypertension (PAH)- Drug Development Pipeline Study” provides in-depth analysis and update information on Pulmonary Arterial Hypertension (PAH) pipeline drugs. Current status of all the drugs in the Pulmonary Arterial Hypertension (PAH) pipeline is provided in the research work.

The report provides detailed analysis of Pulmonary Arterial Hypertension (PAH) pipeline including companies involved, drugs in different stages of development, drug development details across regions (Region (North America, Europe, Asia Pacific and Rest of the World). Further, the Pulmonary Arterial Hypertension (PAH) report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Pulmonary Arterial Hypertension (PAH) industry.

- All latest industry developments and their impact on projects and companies
- Complete overview of global Pulmonary Arterial Hypertension (PAH) therapy options and treatments
- The pipeline study reviews drug details for Pulmonary Arterial Hypertension (PAH) by developing companies, institutions, mechanism of action, Target, Route, Phase (pre-clinical/ Discovery, Phase 1, Phase 2, Phase 3, Pre-Registration, IND/ NDA), molecule
- Mergers, Acquisitions, licensing, co-development and project acquisition news for Pulmonary Arterial Hypertension (PAH) market
- Pulmonary Arterial Hypertension (PAH) drugs being developed in combination with other drugs are also detailed
- Company wise drugs listed with their current status, partners and news updates

Executive Summary
Pulmonary Arterial Hypertension pipeline comprises of 53 drugs under development as of March 2018. Of these, 15 drugs are in Phase 1 and 9 drugs in phase 2, 5 drugs in Phase 3. Further, 19 drugs are in Pre-clinical stage and 4 drugs in research phase. One drug is in pre-registration stage.

60 companies are developing the pipeline for Pulmonary Arterial Hypertension. Of this, MORPHOGEN-IX Limited, Mifcare.ca, Galectin Therapeutics Inc, and GlaxoSmithKline Pharmaceuticals Ltd have highest number of compounds in pipeline. Mechanism of Action of most of the therapeutic candidates is prostacyclin analogue.
Nine compounds have been awarded orphan drug status for PAH.

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.